The t(8;21) translocation is one of the most frequent translocations in acute myeloid leukaemia (AML), giving rise to the AML1-ETO fusion protein (or RUNX1-CBF2T1). This abnormality is associated with myelocytic leukaemia with dysplastic granulopoiesis. Here, we demonstrate that when expressed in a normal human (CD34 þ ) progenitor population, AML1-ETO selectively inhibits granulocyte colony formation but not monocyte colony formation. In bulk liquid culture, we found that though AML1-ETO transiently inhibited the proliferation of CD34 þ cells, it promoted long-term growth of myeloid cells for more than 80 days, suggesting that differentiation was inhibited. In support of this, cultures expressing AML1-ETO demonstrated enhanced retention of colony-forming capacity. Phenotypic examination of AML1-ETO cultures revealed a defect in granulocytic differentiation in terms of retention of CD34 þ cells within the culture and delayed CD11b upregulation. Morphologically, granulocyte terminal differentiation in AML1-ETO-expressing cells was inhibited by 8375%, giving rise to a build-up of early to intermediate granulocytes that exhibited a number of morphological features associated with t(8;21) leukaemias. In contrast, AML1-ETO had little or no effect on monocytic differentiation. Taken together, these results suggest that expression of AML1-ETO selectively inhibits the differentiation of granulocytic cells and promoted extensive self-renewal, supporting a causal role for t(8;21) translocations in leukaemogenesis.
Introduction
Chromosomal translocations are frequently observed in the development of human leukaemias. 1 The translocation (8;21)(q22;q22) is one of the most frequent chromosomal abnormalities associated with acute myeloid leukaemia (AML), and patients with this abnormality typically have bone marrow morphology corresponding to the M2 subtype of the FAB classification. 2 The characteristic morphologic features include abnormal granulopoiesis defined as the presence of myelocytes and metamyelocytes with homogeneous salmon-coloured granules, Auer rods, irregular nuclear shape, high myeloperoxidase activity and pseudo-Pelger-Huët anomaly of the nuclei. 3 The t(8;21) translocation, found in approximately 12% of patients with AML, results in the fusion of the AML1 gene (aka CBFA2 or RUNX1) at chromosome band 21q22 with the ETO (aka MTG8) gene at chromosome band 8q22. 4 Antisense experiments have shown that AML1-ETO acts dominantly over AML1 and may contribute to a leukaemic phenotype by inhibiting differentiation of cells in myeloid lineage. 5 Further, mice heterozygous for AML1-ETO have demonstrated that expression of AML1-ETO blocks AML1-dependent transcription in a dominant-repressive manner 6, 7 and displayed a phenotype that mimics AML1 knockout mice, 8, 9 in that they died during early embryogenesis mainly due to a complete lack of foetal liver haematopoiesis. However, in contrast to AML1 knockout embryos, the same stage yolk sac cells from AML1-ETO knockin mice were able to form dysplastic haematopoietic progenitors that had an abnormally high selfrenewal capacity in vitro, suggesting that some functions of AML1 may be retained in cells expressing AML1-ETO. 6 Conditional expression of AML1-ETO in adult transgenic mice have shown no overt haematopoietic abnormalities. However, cells from these mice did exhibit an enhanced replating potential again suggesting that AML1-ETO was able to promote self-renewal of myeloid cells. 6, 10, 11 Recently, De Guzman et al 12 demonstrated that animals expressing AML1-ETO in haematopoietic stem cells capitulate many of the developmental abnormalities seen in human t(8;21) but require additional secondary mutations for progression of the disease to AML. The effect of AML1-ETO on normal human cells has been less well studied, though Mulloy et al 13 have demonstrated that this fusion protein was able to promote the expansion of human cobblestone area-forming cells, suggesting that AML1-ETO is also able to promote self-renewal of human stem cells. Our own contribution has been to study how AML1-ETO influences lineage development of human cells. Previously, we have shown that AML1-ETO is able to block erythroid differentiation and allow extensive self-renewal of erythroblasts.
14 Here, we have investigated the effect of AML1-ETO on granulocyte and monocytic growth. Again we have observed that AML1-ETO expression profoundly affects development, but these effects are largely restricted to granulocytic progenitors with little or no observable effect on monocytic progenitor development. The data therefore suggest that the common manifestation of granulocytic abnormalities associated with t(8;21) leukaemia is directly attributable to the influence of the AML1-ETO fusion.
Methods (also see supplemental methods)

Generation and expression of retrovirus
The PINCO expression vector coexpressing AML1-ETO and green fluorescent protein (GFP) from an internal CMV promoter was created as previously described. 14, 15 Generation of human CD34 þ cells expressing AML1-ETO
Human CD34
þ cells (495% pure) were derived from cord blood mononuclear cells using MiniMACS (Miltenyi Biotec, Surrey, UK) according to the manufacturer's instructions. These cells were subsequently cultured overnight and transduced as previously described.
14 In this way, two cultures were derived from each CD34 þ preparation: control (expressing GFP alone) and AML1-ETO transduced. Following infection, cultures were maintained in growth medium containing 5 ng/ml of IL-3, SCF and G/GM-CSF. Colony assays were initiated on days 3, 6, 9 and 16 by limiting dilution in 96 U plates (0.3 cells/well) in the same liquid medium containing IL-3, SCF and G/GM-CSF and incubated at 371C with 5% CO 2 . Individual colonies (450 cells) were harvested after 7 or 14 days following plating and were scored and analysed for differentiation (see 'Cell surface phenotype and differentiation analysis').
Cell surface phenotype and differentiation analysis
At the time points indicated, liquid cultures were analysed by four-colour immunophenotypic analysis. Cells were stained with CD13-APC (Leinco Technologies, St Louis, MO, USA) in combination with M-CSF-R-biotin (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) and one of the following PE-labelled antibodies (Dako, Ely, UK ): CD11b, CD14, CD19, CD34 or CD56; biotinylated M-CSF-R was subsequently labelled with Streptavidin-PerCP-Cy5.5 (BD Biosciences, Oxford, UK). Individual colonies were aspirated and stained with CD15-biotin (Sigma, Poole, Dorset, UK) and CD14-APC (Leinco); biotinylated CD15 was subsequently labelled with Neutravidin-PE (Molecular Probes, Eugene, OR, USA). Colonies were identified as monocytes (CD15 lo , CD14 
Data analysis
Flow cytometric data were analysed using WinMDI (Joe Trotter, Pharmingen, San Diego, CA, USA). The threshold for GFP positivity was determined from the autofluorescence of GFPnegative cells in mock-transduced cultures; for antibody labelled cells, this was determined from control stained cells (in each case, set to 95% of controls). Significance of difference was tested using the Students t-test.
Results
Expression of GFP and AML1-ETO in human CD34
þ cells To investigate the effects of the AML1-ETO fusion protein in human primary myeloid development, we retrovirally infected human CD34
þ progenitor cells with a recombinant retrovirus expressing either GFP alone (control) or the AML1-ETO fusion gene in combination with GFP (Supplemental Figure S1A) . Following infection (day 3), flow cytometric analysis demonstrated that these cultures consisted of predominantly CD34 þ cells of which greater than 70% were GFP positive (supplemental Figure S1B ). To confirm the expression of AML1-ETO in transduced human myeloid cells, we performed RT-PCR analysis. As shown in supplemental Figure S1C , the AML1-ETO fragment was clearly detected in cells transduced with this fusion gene, while absent in cells transduced with GFP alone. In addition, expression of AML1-ETO RNA was also confirmed in AML1-ETO-transduced cells after 15 and 43 days of culture (data not shown).
AML1-ETO selectively suppresses granulocytic colony formation
Having generated a population of retrovirally transduced human CD34 þ cells, we determined the effects of AML1-ETO expression on myelopoiesis. First, we assessed the myeloid colony-forming capacity of these cells in liquid medium containing IL-3, SCF and G/GM-CSF. Colony assays were initiated on days 3, 6, 9 and 16 of culture and individual colonies were analysed after 7 days. Typical flow cytometric data is shown in Figure 1a . The expression of AML1-ETO significantly (Po0.05) suppressed granulocytic colony formation by 41% in cultures plated on day 3, when compared to the control (Figure 1b ; left panel); in each case, the granulocytic colonies analysed were CD15 hi , CD14 lo , GFP þ . In order to exclude the possibility that this reduced colony-forming efficiency was a result of slow growth, we analysed colonyforming efficiency of day 3 cells after 14 days. However, we still observed a similar inhibition of granulocytic colony-forming efficiency (50% reduction compared to the GFP control, data not shown). These data suggest that the inhibitory effect of AML1-ETO on granulocytic colony-forming efficiency did not arise simply by reduction in growth rate. In contrast to this inhibitory effect, we found that cells expressing AML1-ETO demonstrated better retention of granulocyte colony-forming ability than control cultures, such that the reduction in colonyforming efficiency was less pronounced as the cells were plated at later time points. By the second week of culture, granulocytic colony-forming efficiency exceeded that of control cultures, although not significantly ( Figure 1b ). These data suggest that despite inhibiting granulocyte colony formation, AML1-ETO may at the same time promote the self-renewal of granulocyte colony-forming cells. In contrast to its effect on granulocyte colony-forming ability, we observed no significant effect of AML1-ETO expression on monocytic colony formation (CD15 lo , CD14 hi , GFP þ ) when plated at 3 or 6 days ( Figure 1b ). Again we observed an increase in monocyte colony-forming efficiency when AML1-ETO cells were plated at days 9 and 16, suggesting that this fusion gene may also affect the self-renewal of cells with monocyte colony-forming capacity. Overall, these data suggest that AML1-ETO specifically inhibits the formation of granulocytic colonies, but at the same time it promotes the selfrenewal of a subpopulation of cells with colony-forming capacity.
Expression of AML1-ETO promotes amplification of immature granulocytes
In order to characterise in more detail the effect of AML1-ETO expression on human myeloid development, we examined the effect of the AML1-ETO fusion protein on myelopoiesis in bulk liquid culture. Under these conditions, control cultures (GFP þ ) proliferated rapidly for 30 days, following which the cells became growth arrested (Supplemental Figure S2) . In contrast, we found that though expression of AML1-ETO transiently inhibited growth over the first 6 days of culture (Po0.01), cells continued to proliferate for more than 70 days, resulting in a 5 Â 10 3 -fold expansion over that observed for control cells (which demonstrated no net proliferation beyond day 30).
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Throughout this period, the cells remained cytokine dependent both for survival and proliferation.
In order to examine the morphology of these cells, we sorted day 17 cultures for GFP þ and examined their morphology (Figure 2a) . The majority of AML1-ETO transduced cells had an immature myeloid morphology with 3176% monocytes, whereas the control cells had terminally differentiated into monocytes (2877%) and segmented/banded neutrophils. AML1-ETO-expressing cells appeared very granular which frequently disturbed nuclear morphology (Figure 2b ). In addition, these cells had numerous nucleoli and a high nuclear to cytoplasmic ratio. Differential counts indicated that granulocyte terminal differentiation in AML1-ETO-expressing cells was inhibited by 8375% (Po0.01), giving rise to a build-up of early to intermediate granulocytes (Figure 2c ) which were phenotypically CD11b
The AML1-ETO-expressing cells maintained this appearance throughout the prolonged period of expansion. Despite the reduced capacity of these cells to form terminally differentiated neutrophils, there was no morphological evidence of any effect on mature monocytes/macrophages differentiation (data not shown).
Expression of AML1-ETO disturbs granulocytic differentiation
The above data indicated that AML1-ETO expression was able to promote the expansion of myeloid cells. We next examined whether expression of AML1-ETO differentially affected the development of granulocytes and monocytes. By following changes in cell-surface marker expression in these cultures by 
) and mixed granulocytic/monocytic (G/M) colonies. GM colonies were only present at low frequency (o8%), therefore rather than categorising these separately, they were defined as monocyte or granulocyte depending on the population predominating (in this instance monocyte). Quadrants delimit background fluorescence of control-stained-transduced cells. 
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A Tonks et al four-colour cytometric analysis, it was possible to monitor the differentiated status of these cells throughout development ( Figure 3) . To discriminate the granulocyte and monocyte population, we labelled cultures with antibody to macrophage-colony stimulating factor-receptor (M-CSF-R aka CSF-1R). In the leucocyte population, expression of this growth factor receptor is restricted to cells committed to monocyte development. 16 For both granulocytic and monocytic cells, AML1-ETO caused a transient inhibition of growth over days 3-6 that accounted for the 2-3-fold decrease in total cell numbers seen at day 13 (Figures 4a and b) . At later time points, expression of AML1-ETO promoted the expansion of granulocytic cells and to a lesser extent that of monocytic cells. Owing to the differentiation of the cells within the culture and the concomitant increase in autofluorescence, it became technically difficult to continue to use the panel of lineage markers to differentiate between monocytes and granulocytes past day 17. These data suggest that although AML1-ETO transiently inhibited the growth of both granulocytic and monocytic cells, this in itself maybe insufficient to explain the reduced granulocytic colony-forming efficiency observed on day 3 cells which only affected granulocytic colony-forming cells. However, the magnitude of the growth inhibition imposed by AML1-ETO was greatest in the granulocytic lineage.
Normal myeloid development is associated with loss of CD34 expression and upregulation of CD11b. Monocytic differentiation is also associated with upregulation of CD14 expression (Figures 3 and 4h) . We found that AML1-ETO expression caused a statistically significant retention of CD34 expression (Po0.01) on granulocytic cells and also reduced the expression of CD11b (Po0.01) when analysed on day 9 (Figures 4c and d,  respectively) . However, retention of CD34 positivity and failure to upregulate CD11b was temporary since these markers were expressed at similar frequencies to control cells by day 17 of culture. This data corresponds to the low frequency of mature neutrophils observed in the morphologic examination of Wrights-Giemsa-stained cytospins ( Figure 2 ). As would be expected, we found generally low levels of CD14 expression on this population (Figure 4e ). In contrast, to the effect on the granulocytic cells, we found no significant abnormality in differentiation antigen expression (CD11b, CD14) on monocytic cells expressing AML1-ETO, although we did observe a transient retention of CD34 (significant at day 6, Po0.05). Contradictory evidence exists as to whether expression of AML1-ETO increases 17 or decreases 18 M-CSF-R expression; however, we observed no such effects in this context. t(8;21) leukaemia is frequently associated with aberrant expression of the lymphoid antigens, CD19 and CD56. 19, 20 We therefore examined whether AML1-ETO may itself induce expression of these antigens in myeloid cells. Cultures were examined for the expression of these antigens at days 6, 17, 44 and 80, but found no significant expression of either CD19 or CD56 (not shown). Taken together, these data suggest that AML1-ETO expression was able to specifically inhibit terminal neutrophil differentiation.
AML1-ETO is able to promote the self renewal of a distinct population of both myeloid and erythroid cells
Previously we have reported that expression of AML1-ETO in erythroid progenitors (CD34 þ , 13 lo ) was able to promote extensive self-renewal of this population.
14 In order to determine whether the cells described here represent a distinct population, we compared their properties in parallel by comparing AML1-ETO-transduced cultures derived from both CD34 þ ,CD13 lo and CD34 þ , CD13 hi populations. In each case, after 23 days, cultures expressing AML1-ETO continued to proliferate, whereas control cultures showed no net growth beyond days 15 and 28, respectively (Figure 5a ), indicating that, as expected, AML1-ETO was able to promote the self-renewal of both of these populations. Morphologically, these cells were distinguishable mainly by the abundance of granules in the CD13 hi -derived population, which often obscured the nuclear morphology (Figure 5b) . One test frequently used to distinguish w Po0.01 indicates statistical significance.
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myeloid cells is the expression of myeloperoxidase (present in the azurophilic granules of neutrophils and in the lysosomes of monocytes). As expected from the morphology, we found that expression of this enzyme was largely restricted to the CD13 hi -derived population, with a low frequency of expression in the CD13 lo -derived population being consistent with the small number of myeloid cells present in these cultures (Figure 5c) . Immunophenotypically, the majority of CD13 lo cells were also CD14 lo (86%) and CD11b lo (60%), while those cells sorted for CD13 hi were CD14 hi (88%) and CD11b hi (70%). Taken together, these data suggest that AML1-ETO independently promotes the self-renewal of both myeloid and erythroid cells derived from a CD34 þ population.
Discussion
The effect of AML1-ETO expression on the development of haematopoietic progenitor cells has been studied in numerous models. 6, [11] [12] [13] [14] However, the expression of this fusion gene and its consequences for human monocyte or granulocyte development has not been examined. This study demonstrated that expression of AML1-ETO in human CD34 þ cells inhibited the formation of granulocytic colonies in vitro. Previously, similar data using murine bone marrow cells from 5-fluorouracil-treated mice infected with AML1-ETO retrovirus were also reported to generate fewer myeloid colonies. 6 In addition, our data parallels findings by Mulloy et al 13 , who demonstrated that AML1-ETO expression in human CD34 þ cells decreased myeloid colony formation by 5-10-fold and also observed a negative effect on proliferation in bulk liquid culture. However, these studies did not discriminate between the effects of AML1-ETO expression on granulocytic and monocytic cells. We show here that AML1-ETO selectively inhibits granulocyte colony formation. We also observed that with extended culture, the suppressive effect of AML1-ETO on colony formation was negated, probably due to the promotion of self-renewal of colony-forming cells rather than to any inherent improvement of their colony-forming capacity. This latter interpretation would be supported by Rhoades et al 11 who demonstrated, using a conditional w Po0.01 indicates statistical significance.
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transgenic mouse model, that though AML1-ETO promoted colony formation during serial replatings, colony formation of these replated cells was considerably enhanced by subsequently suppressing AML1-ETO expression. The basis for this reduced colony-forming capacity could be attributed to the transient inhibition of proliferation by AML1-ETO, which we observed in bulk liquid culture and which has been previously reported for a number of other cell types. 21 However, since this also affected monocytic progenitors whose colony-forming capacity was not inhibited by AML1-ETO, it suggests that this alone was not responsible for inhibition of colony formation. Moreover, colony formation was still reduced when cells were plated on day 6, at which time no antiproliferative effect was observed. These data suggest that it is more likely to be related to the selective disruption of granulocytic development (discussed below). A possibility for the inhibition of proliferation observed was that AML1-ETO expression promoted the apoptotic death of these cells during their development. However, we found no evidence to support this in terms of the frequency of morphologically apoptotic cells (in agreement with our previous observations of erythroid cells 23 ). Similarly, we previously reported that AML1-ETO also results in complete abrogation of erythroid colony formation, while at the same time it promoted extensive growth in bulk culture.
14 This discrepancy between the effects on colony formation vs growth in bulk culture suggests that AML1-ETO may impose additional stresses on cells growing under clonal conditions or that paracrine factors are necessary to perpetuate the growth of these cells.
That AML1-ETO promoted the expansion of immature granulocytes was supported by the observation that expression of this fusion gene promoted developmental dysfunction of granulocytes but not monocytes. Morphological examination demonstrated that granulocyte terminal differentiation in AML1-ETO-expressing cells was inhibited giving rise to a build-up of early to intermediate granulocytes and this was supported by cytometric analysis which showed a delay in CD11b upregulation. The morphology of AML1-ETO-transduced cells in this study correlates in a number of respects with the common morphological features found in t(8;21) leukaemic patients such as abundant basophilic cytoplasm containing large pink-or salmon-coloured granules and abnormal nuclear segmentation. Our data also support Schweiger et al 22 who demonstrated that transplantation of retrovirally transduced mouse HSC with AML1-ETO gave rise to impairment of granulocytic development and accumulation of myeloblasts in the bone marrow. Impairment of granulocytic differentiation was also evident in the growth of colonies with a decrease in CFU-G and a relative increase in CFU-M, which is in agreement with our data. A number of factors may explain why these observations have not previously been made in the transgenic mice models and these are discussed by these authors in their paper. 22 Taken together, these results suggest that expression of AML1-ETO selectively suppresses the differentiation of granulocytic cells and allows extensive self-renewal of immature granulocytes to take place. The mechanism for this selective effect may reflect the ability of AML1-ETO to inhibit the activity of the C/EBPa transcription factor. 23 C/EBPa is thought to be critical for neutrophil development, but is not apparently required for monocytic growth 24 despite the fact that this transcription factor is thought to play a role in the expression of a variety of genes associated with monocytic development; 25 indeed overexpression of C/ EBPa has been shown to block monocyte differentiation. 26 These data suggest that the requirement for this factor may be redundant in monocyte development. It is also interesting to note that abnormalities of the monocytic lineage are rarely detected in t(8;21) patients. 27 Previously we reported that expression of AML1-ETO was also able to promote developmental arrest and extensive selfrenewal of erythroid progenitors in a similar manner to its effect on granulocytic cells, in each case giving rise to an expanded population of immature cells. 14 In this study, we demonstrated that each of these populations were distinguishable by morphology, immunophenotype and myeloperoxidase activity. These data support previous studies which show that AML1-ETO AML1-ETO inhibits human granulocyte differentiation A Tonks et al is able to disrupt the development of both granulocytic and erythroid lineages in a mouse model. 22 We also observed that erythroblasts expressing AML1-ETO were markedly dysplastic. Interestingly, t(8;21)-positive AML M2 is unusual in the high degree of dysplastic maturation observed and this includes the erythroid lineage in both leukaemia and preleukaemic patients expressing this translocation. 27, 28 Our data suggest that this translocation alone may be sufficient to inhibit the differentiation of normal human cells as well as promoting their selfrenewal. A number of previous studies have indicated that AML1-ETO may promote self-renewal of primitive haematopoietic cells. 6, 10, 12, 13 Our data indicate that this fusion gene may also promote self-renewal within a population of cells that is devoid of primitive cells (both morphologically and phenotypically). Thus, AML1-ETO, in common with PML-RARa, BCR-ABL and MLL-ENL, may have the capacity to confer self-renewing activity to cells with a committed progenitor phenotype. 29 Nevertheless, it is clear from a number of studies that expression of AML1-ETO alone is insufficient for leukaemic transformation. 10, 11, 30 In summary, we demonstrate that expression of AML1-ETO in human CD34
þ cells selectively inhibits the differentiation of granulocytic cells and promotes the self-renewal of these cells. These data provide a clear demonstration of the capacity of this fusion gene to promote self-renewal of progenitor cells and may provide a tractable model for determining the mechanism by which AML1-ETO influences self-renewal in normal human cells. 
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